Thursday: Three Morning Takes
The New York Times revealed that biologists are using AI chatbots to research how to modify and release deadly pathogens, highlighting a growing bio‑security risk. In New York, communist mayor Zohran Mamdani announced a second‑home tax targeting hedge‑fund titan Ken Griffin, whose $6 billion Manhattan development and recent moon‑mission film have drawn political fire. Meanwhile, California’s high‑speed rail project faces a $1 billion detour to avoid the Cesar Chavez National Monument after allegations against Chavez, inflating an already massive infrastructure budget.
Seaport Therapeutics (SPTX) IPO Deck
Seaport Therapeutics, a clinical‑stage biotech firm, is preparing an initial public offering to fund its oral drug program targeting major neuropsychiatric conditions such as depression and anxiety. The company’s IPO deck emphasizes a “proven path” in neuroscience, highlighting pre‑clinical data...
The Biotech Bi-Weekly: A Virtual Biology Initiative, a New Discovery Grant and a Protein Supplier to Watch in Cancer Research...
The biotech bi‑weekly highlights a wave of new funding and tools, starting with Biohub’s $500 million five‑year Virtual Biology Initiative to generate global multimodal datasets for predictive biology. Zymo Research launched the Fecal Microbiome Discovery Grant to support early‑stage researchers, while...
New iPSC Differentiation Kits for Neuroscience Research
AMSBIO introduced the Quick‑Glia™ product line, iPSC‑derived glial cell kits designed for neuroscience research. The kits convert human induced pluripotent stem cells into functional astrocytes or microglia in 1–2 weeks, delivering high‑purity, cryopreserved cells ready for disease modeling and drug...
South African Startup Scales Up Growth Factor for Low-Cost Cultivated Meat
South Africa’s biotech startup Immobazyme, in partnership with the government‑run CSIR, has successfully scaled production of fibroblast growth factor 2 (FGF‑2) using a 50‑litre bioreactor. The protein, a costly growth factor essential for cultivated‑meat cell culture, was produced at commercial‑grade...
Buried in Soil, a 100-Million-Year-Old Bacterial Toxin Could Reshape Pest Control and Antibiotic Discovery
Researchers from McMaster, Harvard, Yale and European partners have identified a new class of insect‑killing proteins, SAIPs, produced by rare Streptomyces strains. These toxins, structurally distant from diphtheria toxin, target an insect‑specific surface protein called Flower, leaving humans unharmed. The...
EnVVeno Medical Secures FDA IDE Approval for Venous Valve Study
enVVeno Medical has secured FDA investigational device exemption (IDE) approval to launch its pivotal Transcatheter Venous Valve Endoprosthesis (TAVVE) study, targeting severe chronic venous insufficiency (CVI). The trial will begin later this year with a ten‑patient safety cohort, followed by...
Precision Begins Patient Enrolment for FUNCTION-DMD Trial
Precision BioSciences has activated Arkansas Children’s Hospital as the inaugural site for its Phase I/II FUNCTION‑DMD trial, enrolling boys aged two to seven with Duchenne muscular dystrophy. The study tests PBGENE‑DMD, a first‑in‑class in‑vivo gene‑editing therapy that removes exons 45‑55 to restore...
How Epic Bio Is Leveraging CRISPR without Cutting DNA
Epic Bio, founded by Stanford professor Stanley Qi, is developing an epigenetic editing platform called GEMS that uses the smallest known Cas protein to modulate gene expression without cutting DNA. The system can be delivered in a single viral vector...
Re: Efficacy and Safety of VPM1002 and Immuvac in Preventing Tuberculosis: Phase 3 Randomised Clinical Trial (PreVenTB Trial)
The phase‑3 PreVenTB trial found that neither VPM1002 nor Immuvac reduced microbiologically confirmed tuberculosis, missing its primary efficacy endpoint. The authors of a BMJ rapid response highlight that the headline claim of 50% efficacy against extrapulmonary TB rests on only...
Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)
The European Commission has granted approval for Poherdy, a 420 mg/14 mL interchangeable biosimilar of pertuzumab (Perjeta), covering all approved indications. The decision rests on extensive analytical, pharmacokinetic, efficacy, safety and immunogenicity data that demonstrate equivalence to the reference product. Henlius has...
XPRIZE Healthspan Names Top 100 Teams Advancing Healthy Aging
The XPRIZE Healthspan competition announced its top 100 teams, spotlighting the core innovations of the 40 Milestone 1 award‑winning entrants. These teams are pursuing a spectrum of strategies—from mitochondrial‑targeted small molecules and metformin‑rapamycin combos to AI‑driven nutrition plans, senolytic drugs, and...
SportLinc Receives FDA Clearance: Lincotek Targets Orthopedic OEM Market
Lincotek’s SportLinc Syndesmosis Device has secured FDA 510(k) clearance (K252081), enabling commercial launch for ankle syndesmosis injuries. The single‑use system combines a high‑molecular‑weight polyethylene suture with low‑profile titanium buttons and arrives preloaded in a sterile inserter, streamlining operating‑room workflow. Lincotek...
A Study in Regulatory Conservatism versus Clinical Innovation
At today’s ODAC meeting, the FDA will review AstraZeneca’s oral selective estrogen receptor degrader camizestrant for hormone‑receptor‑positive, HER2‑negative breast cancer with ESR1 mutations. Late‑stage data showed a 56% reduction in risk of disease progression and consistent safety, along with improved...
Defect-Engineered Pt/Nb2O5 Boosts Radical-Driven Benzimidazole Production and Hydrogen Evolution Efficiency
Researchers have created a defect‑engineered Pt/Nb₂O₅ catalyst with abundant oxygen vacancies and platinum nanoparticles that dramatically improves photocatalytic benzimidazole synthesis and concurrent hydrogen evolution. The system delivers 4.0 mmol g⁻¹ h⁻¹ production of 2‑methylbenzimidazole and 10.2 mmol g⁻¹ h⁻¹ hydrogen under mild light, surpassing prior benchmarks....
DeNovix Launches Squid™ Full Range Pipette: A Single Device Covering 1 – 1000 µL
DeNovix unveiled the Squid™ Full Range Pipette, a single instrument that handles volumes from 1 µL to 1000 µL, effectively consolidating three to five conventional pipettes. The device uses Dynamic Volume Control™ with a patented tip selector, allowing users to switch between...
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
A wave of sizable financing rounds swept the biotech sector in late April 2026, with more than $1.3 billion pledged across 15 companies. Beeline Medicines led the pack with a $300 million Series A to advance lupus‑focused small‑molecule and protein therapeutics, while Sidewinder...
Single-Cell Sequencing Reveals Why some CAR-T Therapies Succeed While Others Fail
Researchers reviewed 44 single‑cell RNA sequencing studies covering about 500 patients to pinpoint cellular traits linked to CAR‑T therapy outcomes. The analysis identified exhaustion marker expression, low memory‑like cell fractions, and limited clonal diversity as hallmarks of relapse, while persistent,...
Cardiovascular Health 2026
Recent studies highlight pitavastatin’s pleiotropic benefits beyond LDL‑C reduction, including functional HDL elevation, enhanced cholesterol‑efflux capacity, and antioxidative actions in dyslipidemic patients. Pre‑clinical work shows the drug strengthens blood‑brain barrier integrity and mitigates lipopolysaccharide‑induced BBB dysfunction, suggesting neuroprotective potential. Real‑world...
Global Lassa Virus Research Reveals Critical Knowledge Gaps and Regional Disparities
A new global assessment of Lassa fever research highlights stark knowledge gaps and uneven investment across endemic regions. The report finds that only three of the seven high‑burden countries host active surveillance sites, and funding for Lassa studies trails behind...
Tackling Drug Resistance Must Become Biotech’s Next Frontier
Drug resistance underlies roughly 90% of the 600,000 cancer deaths in the United States each year, limiting the durability of modern therapies. Kairos Pharma, founded in 2013, is focusing on the biology of resistance with its candidate ENV‑105, which aims...
Your Weekly TechBio News: High-Throughput Screening
High‑Throughput Screening (HTS) remains a cornerstone of modern drug discovery, allowing researchers to evaluate millions of chemical compounds against biological targets in a single campaign. Recent advances in robotics, miniaturized assay formats, and cloud‑based data pipelines have dramatically increased throughput...
Generally Good Indian Pharma Companies
An audit of top‑tier Indian generic manufacturers evaluated options for 20 therapeutic compounds, ranking firms by market capitalization, API vertical integration, ANDA volume, and GMP compliance. Cipla, Abbott, Sun Pharma, Zydus, Biocon and others were highlighted for specific products such...
Restoring Vision with Stem Cell–Derived Retinal Cells by Overcoming ILM Barrier
Researchers have shown that disrupting the internal limiting membrane (ILM) enables transplanted human pluripotent stem cell‑derived retinal ganglion cells (hRGCs) to survive, migrate, and mature in the retina of mice, rats and non‑human primates. In eyes with a genetically incomplete...
New Copper Nanozyme Shows Powerful Tumor Suppression with High Precision
Researchers at the Chinese Academy of Sciences have created a coordinatively unsaturated copper single‑atom nanozyme (Cu‑N₂‑CDs) that exhibits markedly higher catalytic activity than traditional Cu‑N₄ nanozymes. The unsaturated Cu‑N₂ sites boost H₂O₂ adsorption by 3.49 times and generate hydroxyl radicals 3.62 times...
ONAVIDA Study Finds High‑Protein Oral Supplement Improves Recovery in Malnourished Cancer Patients
The ONAVIDA trial, published on 29 April 2026, demonstrated that a novel concentrated high‑protein, high‑calorie oral nutritional supplement (cHPHC‑ONS) significantly enhanced nutritional and morphofunctional recovery in 230 malnourished cancer patients over three months. The prospective, multicenter study combined the supplement...
Astorg to Acquire Thermo Fisher’s Microbiology Unit for $1.1 Billion
European private‑equity firm Astorg has signed a deal to purchase Thermo Fisher Scientific’s microbiology business for roughly $1.075 billion in cash and a $50 million seller note. The transaction, slated to close in the second half of the year, positions Astorg to...
Survodutide Shows 16.6% Weight Loss in Phase 3 Trial, Boosting Obesity Drug Race
Zealand Pharma reported that its dual GLP‑1/glucagon agonist survodutide produced an average 16.6% body‑weight reduction in a Phase 3 obesity trial. The data, presented from the SYNCHRONIZE‑1 study, also showed 85.1% of patients lost at least 5% of weight versus 38.8%...
3Shape's AI Dental Imaging Software Gets FDA 510(k) Clearance
Denmark‑based 3Shape announced that the U.S. FDA granted 510(k) clearance for its Dx dental imaging suite, enabling American dental clinics to deploy AI‑assistive diagnostics for caries, plaque, wear and gingival recession. The approval opens a new revenue channel and marks...
NeoGenomics Q1 2026 Revenue Jumps 11% as COO Warren Stone Charts Aggressive Sales Expansion
NeoGenomics reported first‑quarter 2026 revenue of $186.7 million, an 11% year‑over‑year increase that beat guidance and prompted a lift in full‑year outlook. President and COO Warren Stone used the call to unveil a sales‑force expansion and deeper community‑oncology coverage aimed at...
FDA Launches Real‑Time Clinical Trial Monitoring to Accelerate Drug Reviews
The U.S. Food and Drug Administration announced the completion of its first real‑time clinical trial monitoring tests, partnering with AstraZeneca and Amgen to stream safety and efficacy data live to regulators. The initiative uses AI and electronic health‑record integration to...
Dr. Reddy’s Announces Health Canada Approval of Generic Semaglutide Injection
Dr. Reddy’s Laboratories received a Notice of Compliance from Health Canada, becoming the first firm to secure market authorization for a generic semaglutide injection in Canada. The approval covers both 2 mg and 4 mg pen formulations, and the company is preparing...
GSK‑Ionis Antisense Drug Bepirovirsen Gets FDA Priority Review, Breakthrough Designation
GSK and its partner Ionis Pharmaceuticals announced that the FDA has placed bepirovirsen, an antisense oligonucleotide for chronic hepatitis B, on the priority‑review track and granted it breakthrough therapy designation. The move follows Phase 3 B‑Well data showing statistically significant functional‑cure...
Gene Editing Swaps Whole Genes, Fixes 1,000 Mutations
A new genome editing technique enables efficient replacement of entire genes, allowing correction of up to 1,000 mutations simultaneously by inserting large DNA segments without causing toxic double-strand breaks. genetherapy
Northwestern Chemist Launches Science-Driven Biotech Blog
New biotech blog by a Northwestern medicinal chemist -- debut post is a well-written, science-focused take on $CCCC. Check it out: https://t.co/4Pc5wUUKlO
New Genome Editing Method Could Swap Entire Genes and Correct 1000 Mutations at Once
Scientists have unveiled a new genome‑editing platform called prime assembly that can insert DNA segments up to 11,000 base pairs, enabling the replacement of entire genes rather than single‑point edits. The method uses overlapping flaps to attach donor DNA without...
Biotech Liquidation Opportunities: ENDI, FNCH, LQDA Outlook
Please find Arquitos Capital's Q1 2026 letter below. I discuss opportunities in liquidating biotechs, $ENDI $FNCH and the range of potential outcomes for $LQDA. https://t.co/LJCczZ04W6
Exercise Proven to Reduce Biological (Epigenetic) Age
What is the most established intervention linked to lower biological (epigenetic) age? Exercise A new systematic review @LancetLongevity of 44 studies, >145,000 participants https://t.co/agmAazwDxs
Cartesian Therapeutics Inc (RNAC) Q1 2026 Earnings Call Transcript
Wave Life Sciences reported a Q1 net loss of $46.9 million, with cash reserves of $243.1 million expected to fund operations into 2027. The DMD candidate WVE‑N531 delivered a statistically significant 3.8‑second improvement in time‑to‑rise and 7.8% average dystrophin expression,...
All Life Runs on 20 Amino Acids. These Cells Run Key Machinery on Just 19
Scientists have engineered Escherichia coli to run its ribosome—a core protein‑making machine—using only 19 of the standard 20 amino acids, eliminating isoleucine. The breakthrough leveraged AI tools such as AlphaFold and protein language models to redesign protein sequences without compromising...
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals reported $172 million total revenue for 2025, driven by $124.8 million from its menin inhibitor RevuForge and $151.6 million from the chronic‑GVHD therapy Nictimvo. RevuForge posted 38% quarter‑over‑quarter revenue growth and reached roughly 50% penetration of the KMT2A AML population, while...
Alnylam Pharmaceuticals Inc (ALNY) Q1 2026 Earnings Call Transcript
Alnylam reported a strong Q1 2021 performance, with total product sales reaching $135.8 million, an 89% year‑over‑year increase. ONPATTRO generated $102 million in revenue, growing 13% quarter‑over‑quarter, while newly launched OXLUMO contributed $9 million and GIVLAARI $24.7 million. The company announced positive Phase 3 data...
Pro-Dex Inc (PDEX) Q3 2026 Earnings Call Transcript
Becton Dickinson reported Q3 fiscal 2025 revenue of $5.5 billion, up 8.5% year‑over‑year and 3% organically, while adjusted gross margin rose to 54.8% and adjusted EPS reached $3.68, beating expectations. The company announced a definitive agreement to divest its Biosciences and...
Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Transcript
Kymera Therapeutics reported Q1 2026 revenue of $2.8 million, entirely from its Gilead collaboration, and ended the quarter with $978.7 million in cash, extending its runway into the second half of 2028. The company completed enrollment and dosing for the Phase Ib atopic...
Genome Pioneer Craig Venter Dies: Here’s How He Transformed Science
Craig Venter, the maverick who led the private race to sequence the human genome, died at 79. He pioneered whole‑genome shotgun sequencing, enabling rapid, cost‑effective assembly of DNA and co‑founded Celera Genomics to produce a draft human genome alongside the...
PLANeT: Understanding and Leveraging the Genome of Land Plants for a Sustainable Future
Land plants support ecosystems and human civilization, yet reference genomes exist for only a fraction of taxa—95% of genera, 70% of families and 51% of orders remain unsequenced. The PLANeT initiative proposes an international consortium of about 100 laboratories to...
Angiocrine Signaling Drives Liver Fibrosis: From Mechanism to Early Clinical Translation
Researchers led by Hu et al. discovered that ROCK2 activity in liver sinusoidal endothelial cells is a pivotal driver of liver fibrosis. Single‑cell transcriptomics and knockout models revealed that ROCK2‑mediated cytoskeletal remodeling releases angiocrine factors that activate hepatic stellate cells. Early...
Long-Lived Immune Cells Show Promise Against Cancer in World-First Trial
A world‑first clinical trial tested CAR‑T therapy enriched with stem‑cell memory T cells, a long‑lived immune subset. In a small cohort of 11 patients with refractory blood cancers, five achieved complete remission and one partial remission, outperforming historical outcomes of...
Vaccines May Reduce Alzheimer Risk and Slow Aging
I'm getting two vaccines next week: Tdap and shingles. The Tdap because Kate's family has a newborn and we're visiting. Shingles for the potential longevity benefits. Data we're looking at: 1. Lower Alzheimer risk with vaccination in 1.6 million people,...
CCDC6‑RET Fusion Recycles ADP, Drives Rapid Tumor Activation
The fusion protein CCDC6-RET, implicated in lung and thyroid cancers, can self-activate rapidly and uniquely reuse ADP as an energy source, offering new insight into tumor adaptability and potential therapeutic strategies. cancerbiology